In this research, we studied the molecular mechanism of (3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chroman-7-o through molecular docking, and found that this compound may target multiple glioma-related targets, such as SRC (binding affinity = −8.9 kcal/mol), PTGS2 (binding affinity = −8.9 kcal/mol), and PTK2 (binding affinity = −8.6 kcal/mol). This evidence concerns the gene PTK2 and central nervous system cancer.